[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"crohns-ileocolitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:crohns-ileocolitis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,73,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100557479","early-phase-1-effect-of-statins-on-crohns-disease-100557479",false,"NCT06538649","Effect of Statins on Crohn's Disease","Determining the Therapeutic Potential of Statins on Stricturing Crohn's Disease","Inclusion Criteria:\n\n1. Established diagnosis of stricturing Crohn's disease\n2. Scheduled for surgical resection of terminal ileum strictures at either\n\n   * Stanford University, or\n   * Dr. Phillip Fleshner's colorectal surgery practice in Los Angeles\n\nExclusion Criteria:\n\n1. Pregnant, nursing, or planning to become pregnant in the next 6-12 months\n2. Severe renal dysfunction (stage 5 chronic kidney disease (CKD), end-stage renal disease (ESRD))\n3. Known clinical allergy or prior adverse reaction to statin therapy (e.g., rhabdomyolysis)\n4. Current use of cyclosporine\n5. Current use of statin therapy prior to study initiation\n6. Clinical diagnosis of active liver disease (beyond metabolic dysfunction-associated steatotic liver disease (MASLD)) with unexplained persistent elevations in hepatic transaminase levels\n7. Current use of any of the following medications, without explicit clearance from a treating physician to enroll in the study:\n\n   * Antifungals (e.g., ketoconazole, itraconazole, voriconazole)\n   * Fibrate drugs\n   * Macrolide antibiotics (e.g., erythromycin, clarithromycin)\n   * Protease inhibitors (e.g., ritonavir, lopinavir)\n   * Calcium channel blockers (e.g., verapamil, diltiazem)\n   * Amiodarone\n   * Warfarin\n   * Colchicine","ALL","18 Years","80 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","The goal of this clinical trial is to learn if statins work to prevent strictures in adults with Crohn's disease. The main question it aims to answer is:\n\n* Can statins reduce the formation of strictures in participants with stricturing Crohn's disease?\n\nResearchers will compare statins to a placebo (a look-a-like substance that contains no drug) to see if statins work to prevent strictures from forming. Participants will:\n\n* Take statins or a placebo every day for 6-12 months\n* Visit the clinic for lab tests twice after starting either statins or placebo\n* Complete questionnaires about symptoms and medications\n* Respond to monthly check-ins (via phone call) during participation",[27,28],"Crohn's Ileocolitis","Crohn Disease","RECRUITING","2026-02-23",{"date":32,"type":33},"2026-02-27","ACTUAL",{"date":35,"type":33},"2024-12-12",{"date":37,"type":21},"2028-10-31",{"name":39,"class":40},"Stanford University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":62,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":41},"100464818","personalized-risk-estimation-for-crohns-disease-pre-crohns-implementation-and-feasibility-100464818","NCT05332639","Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility","Inclusion Criteria:\n\n* Ability to give informed consent\n* Ability and willingness to comply with all patient visits and study-related procedures\n* Ability to understand and complete study questionnaires\n* Must have at least one first-degree relative with inflammatory bowel disease (Crohn's disease, ulcerative colitis, or indeterminate colitis\u002FIBD unclassified)\n* Individuals greater than 14 years of age\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Inability to comply with all patient visits and study-related procedures\n* Inability to understand or complete study questionnaires\n* Patients with existing diagnoses of inflammatory bowel disease (ulcerative colitis, Crohn's disease, or indeterminate colitis\u002FIBD unclassified)\n* Evidence of clinical signs or symptoms of inflammatory bowel disease, identified by a modified version of the Harvey-Bradshaw Index for CD activity",true,"14 Years",{"count":51,"type":21},80,[53],"NA","The aim of this study is to develop and assess the feasibility and effect of a web-based, personalized risk-estimation for Crohn's disease (PRE-Crohn's) tool on behaviors and biomarkers associated with risk for Crohn's disease in unaffected first-degree relatives of patients with inflammatory bowel disease. We hypothesize that personalized risk disclosure via the PRE-Crohn's educational tool is both feasible and successful in modifying behaviors associated with Crohn's disease risk and normalizing pre-clinical disease biomarkers when compared to standard Crohn's disease education. Broadly, completion of this project will also help elucidate the role of lifestyle and dietary factors in pre-clinical Crohn's disease development in high-risk individuals, and provide novel insight into potential strategies for disease prevention in this population.",[56,28,57,27,58,59,60,61],"Inflammatory Bowel Diseases","Crohn Colitis","Crohn's Gastritis","Crohn's Jejunitis","Crohn's Duodenitis","Crohn's Esophagitis",[63],"Crohn's disease","2026-01-29",{"date":66,"type":33},"2026-01-30",{"date":68,"type":33},"2025-10-03",{"date":70,"type":21},"2027-11",{"name":72,"class":40},"Massachusetts General Hospital",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":48,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":95,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":103,"leadSponsor":105,"locationsCount":41},"100566456","family-members-at-increased-risk-for-developing-inflammatory-bowel-disease-100566456","NCT06655415","Family Members At INcreased-risk for Developing Inflammatory Bowel Disease","Family Members At INcreased-risk for Developing Inflammatory Bowel Disease (FIND-IBD)","FIND-IBD","Inclusion Criteria:\n\n* Ability to give informed consent\n* Ability to complete all study visits and study-related procedures\n* Ability to understand and complete study questionnaires\n* Must have at least one first-degree relative with inflammatory bowel disease (Crohn's disease, ulcerative colitis, or IBD-unclassified)\n* Age ≥ 14\n\nExclusion Criteria:\n\n* Individuals with existing diagnoses of inflammatory bowel disease (ulcerative colitis, Crohn's disease, or IBD-unclassified)\n* Evidence of clinical signs or symptoms of IBD, which will be identified on pre-screening interview with the study coordinator.",{"count":82,"type":21},50,"10 Years","OBSERVATIONAL","First-degree relatives of people with inflammatory bowel disease (\"IBD,\" including Crohn's disease and ulcerative colitis) have an increased risk for developing IBD themselves. This study will follow unaffected first-degree relatives (who do not have IBD) over time to understand if their behaviors, diet, and biomarkers for IBD can help predict who gets IBD and if IBD can be prevented in these high-risk individuals. Participants will be asked once per year to complete a questionnaire and have their blood, stool, and urine collected. The anticipated length of the study (registry) is approximately 10 years or longer. Parts of this study, such as the questionnaires and stool and urine collection, may be done from home, while other parts, such as the blood draw, will need to be done from Massachusetts General Hospital.",[87,88,89,90,91,92,27,58,59,60,61,93,94],"Inflammatory Bowel Disease (IBD)","Ulcerative Colitis (UC)","IBD-unclassified (IBD-U)","Indeterminate Colitis","Crohn's Disease Colon","Crohn's Colitis","Ulcerative Proctitis","Ulcerative Proctosigmoiditis",[96,97,98,63],"Inflammatory Bowel Disease","IBD","Ulcerative colitis","2024-12-18",{"date":101,"type":33},"2024-12-20",{"date":99,"type":33},{"date":104,"type":21},"2034-12",{"name":72,"class":40},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":41},"100558739","investigation-of-vap-1-expression-and-tissue-blood-flow-by-pet-mri-in-patients-with-crohns-disease-100558739","NCT06555042","Investigation of VAP-1 Expression and Tissue Blood Flow by PET-MRI in Patients With Crohn's Disease","Investigation of VAP-1 Expression and Tissue Blood Flow by Combined [68Ga]DOTA-Siglec-9 and [15O]H2O PET-MRI in Patients With Small Bowel's Crohn's Disease","VAP-PET","Inclusion Criteria:\n\n* Adults between age 18-70\n* Strong clinical suspicion of small bowel Crohn's disease\n* Able and willing to give written informed consent and to comply with the study protocol\n\nExclusion Criteria:\n\n* Pregnant or breast-feeding women\n* Previous capsule retention\n* X-ray investigations during preceding year\n* Patients with metallic implants such as an electronic pacemaker or an implanted infusion pump\n* Known stenosis of the GI-tract\n* Evidence of significant uncontrolled concomitant diseases such as neurological, renal, hepatic, endocrine, or gastrointestinal disorders which, in the opinion of the Investigator, would preclude patient participation\n* Is unable or unwilling to comply with the study protocol for any reason","70 Years",{"count":20,"type":21},"This is an observational, single center, imaging study. The CD patients with active disease will be assessed by \\[68Ga\\]Ga-DOTA-Siglec-9 and \\[15O\\]H2O PET\u002FMRE. Patients with high clinical suspicion of small intestine's CD in outpatient gastroenterology clinic of Turku University Hospital will be recruited. The patients must fulfil the eligibility criteria and give their signed approvement prior to their enrolment into the study.\n\n20 patients with high suspicion of active small bowels CD will be enrolled to being evaluated for potential participation in this study. In patients with diagnosed small bowels CD, PET-MRE will be repeated 3 months after the initial imaging (and based on clinical diagnostic started medication) to verify disease remission\u002Finadequacy of the treatment.\n\nAssessments for CD clinical disease activity will be performed at screening and \\[68Ga\\]Ga-DOTA-Siglec-9 and \\[15O\\]H2O PET\u002FMRE assessments will be performed within a month for each patient.\n\nAfter PET\u002FMRE all patients can be treated according to patients' needs with immunosuppressive drugs. Follow-up visits are organized at after PET\u002FMRE imaging at gastroenterology outpatient clinic.",[28,56,118,57,27,119],"Crohn Disease of Small Intestine","Crohn Disease in Remission",[96,121,63,122,123],"Positron emission tomography","Vascular adhesion protein-1","Intestinal Perfusion","2024-08-14",{"date":126,"type":33},"2024-08-15",{"date":128,"type":21},"2024-09",{"date":130,"type":21},"2026-06-06",{"name":132,"class":133},"Turku University Hospital","OTHER_GOV"]